Bioclinica, a options supplier of medical life science and expertise experience, has acquired Silicon Valley-based Saliency.
Bioclinica will combine the corporate’s AI expertise into its imaging platform to help a rising portfolio of pharmaceutical and medical gadget shoppers. The mixing will goals to speed up picture QC and interpretation, enabling fast growth of digital diagnostics and digital therapeutics.
Dan Gebow, chief innovation officer at Bioclinica, stated: “Purchasers depend on us for time-sensitive expert-level picture interpretation for his or her medical trials to allow them to deal with outcomes. We evaluated a wide range of medical imaging AI platforms and know the Saliency platform is head and shoulders above others available in the market in its potential to ship worth for our shoppers.”
The Saliency platform makes use of algorithms to construct and practice AI fashions from a small variety of de-identified photographs. These newly created fashions can then be used to display, redact, or interpret medical photographs to help a variety of therapeutic areas. This functionality can be embedded into Bioclinica’s present and future imaging options in accordance with EU GDPR and different privateness laws.
Kevin Thomas, MD/PhD, CEO of Saliency, stated: “This integration empowers trade stakeholders with absolutely the newest in medical imaging expertise by delivering customized AI fashions sooner and with extra accuracy.”
The Saliency acquisition solidifies Bioclinica’s place as a supplier of analysis picture expertise and companies to sponsors and Medical Analysis Organizations. The AI integration will create a perpetual studying system that can allow Bioclinica to increase its portfolio and drive new income with its enhanced providing.
Saliency’s co-founders, Kevin Thomas, MD/PhD, candidate at Stanford College College of Drugs and Łukasz Kidziński, PhD, previously of Stanford’s Bioengineering & Statistics, will be part of Bioclinica’s Picture Science crew, additional strengthening the corporate’s medical imaging experience and choices.
Łukasz Kidziński, Saliency’s president and CTO, stated: “We’re proud to mix our state-of-the-art cloud-based instruments with Bioclinica’s unrivalled imaging experience.”
